Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

Journal of the Neurological Sciences

Volumn 343, Issue 1-2, 2014, Pages 120-124

  Vranová, Hana Přikrylová ^a   Hényková, Eva ^a   Kaiserová, Michaela ^a   Menšíková, Kateřina ^a   Vaštík, Miroslav ^a   Mareš, Jan ^a   Hluštík, Petr ^a   Zapletalová, Jana ^a   Strnad, Miroslav ^a   Stejskal, David ^a   Kaňovský, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer disease; Biomarkers; Cerebrospinal fluid; Clusterin; Lewy body dementia; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CLUSTERIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MENTAL HEALTH; MIDDLE AGED; PARKINSON DISEASE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84904247027     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.05.052     Document Type: Article

References (47)

1. K.A. Jellinger Mild cognitive impairment in Parkinson's disease: heterogenous mechanism J Neural Transm 120 2013 127 167
2. M. Emre, D. Aarsland, R. Brown, D.J. Burn, C. Duyckaerts, and Y. Mizuno et al. Clinical diagnostic criteria for dementia associated with Parkinsons disease Mov Disord 22 2007 1689 1707
3. A.I. Troster Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease dementia, early detection, and implication for "mild cognitive impairment" biomarkers Neuropsychol Rev 18 2008 103 119
4. L. Guo, M. Itaya, M. Takanashi, Y. Mizuno, and H. Mori Relationship between Parkinson disease with dementia and dementia with Lewy bodies Parkinsonism Relat Disord 11 2005 305 309
5. D.J. Irwin, M.T. White, J.B. Toledo, S.X. Xie, J.L. Robinson, and V. Van Deerlin et al. Neuropathologic substrates of Parkinson disease dementia Ann Neurol 72 2012 587 598
6. G.M. Halliday, Y.J. Song, and A.J. Harding Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease J Neural Transm 118 2011 713 719
7. S.N. Gomperts, J.J. Locascio, M. Marquie, A.L. Santarlasci, D.M. Rentz, and J. Maye et al. Brain amyloid and cognition in Lewy body diseases Mov Disord 27 2012 965 973
8. H. Přikrylová Vranová, J. Mareš, P. Hluštík, M. Nevrlý, D. Stejskal, and J. Zapletalová et al. Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease J Neural Transm 119 2012 353 362
9. Y. Compta, N. Ibarretxe-Bilbao, J.B. Pereira, C. Junqué, N. Bargalló, and E. Tolosa et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia Parkinsonism Relat Disord 18 2012 941 947
10. J. Gao, X. Huang, Y. Park, A. Hollenbeck, and H. Chen An exploratory study on CLU, CR1 and PICALM and Parkinson disease PLoS One 6 8 2011
11. R. Killick, E.M. Ribe, R. Al-Shawi, B. Malik, C. Hooper, and C. Fernandes et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway Mol Psychiatry 19 2014 88 98
12. A.M. Lidström, C. Hesse, L. Rosengren, P. Fredman, P. Davidsson, and K. Blennow Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke J Alzheimers Dis 3 2001 435 442
13. K. Sasaki, K. Doh-ura, Y. Wakisaka, and T. Iwaki Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alphasynucleinopathies Acta Neuropathol 104 2002 225 230
14. C.L. Maarouf, T.G. Beach, C.H. Adler, H.A. Shill, M.N. Sabbagh, and T. Wu et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects Neurol Res 34 2012 669 676
15. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181 184
16. I.G. McKeith, D.W. Dickson, J. Lowe, and M. Emre O'Brien, J. T., Feldman, H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 2005 1863 1872
17. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
18. O. Spreen, and E. Strauss A compendium of neuropsychological tests 2nd ed. 1998 Oxford University Press New York
19. V. Goel, and J. Grafman Are the frontal lobes implicated in.,planning' functions? Interpreting data from the Tower of Hanoi Neuropsychologia 33 1995 623 642
20. P.M. Mattila, T. Koskela, M. Röyttä, T. Lehtimäki, T.A. Pirttilä, and E. Ilveskoski et al. Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology Acta Neuropathol 96 1998 417 420
21. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease 289 2003 2094 2103
22. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
23. A. Stefani, L. Brusa, E. Olivola, M. Pierantozzi, and A. Martorana CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD J Neural Transm 119 2012 861 875
24. L. Parnetti, P. Tiraboschi, A. Lanari, M. Peducci, C. Padiglioni, and C. D'Amore et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies Biol Psychiatry 64 2008 850 855
25. G. Alves, K. Brønnick, D. Aarsland, K. Blennow, H. Zetterberg, and C. Ballard et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study J Neurol Neurosurg Psychiatry 81 2010 1080 1086
26. B. Holmberg, B. Johnels, K. Blennow, and L. Rosengren Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy Mov Disord 18 2003 186 190
27. B. Mollenhauer, C. Trenkwalder, N. von Ahsen, M. Bibl, P. Steinacker, and P. Brechlin et al. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia Dement Geriatr Cogn Disord 22 2006 200 208
28. H. Přikrylová Vranová, J. Mareš, M. Nevrlý, J. Zapletalová, P. Hluštík, and P. Kaňovský CSF markers of neurodegeneration in Parkinson's disease J Neural Transm 117 2010 1177 1181
29. M. Sjögren, L. Minthon, and P. Davidsson Granérus A-K, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging J Neural Transm 107 2000 563 579
30. A. Siderowf, S.X. Xie, H. Hurtig, D. Weintraub, J. Duda, and A. Chen-Plotkin et al. CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease Neurology 75 2010 1055 1061
31. J.H. Kang, D.J. Irwin, A.S. Chen-Plotkin, A. Siderowf, C. Caspell, and C.S. Coffey et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease JAMA Neurol 70 2013 1277 1287
32. F. Abdi, J.F. Quinn, J. Jankovic, M. McIntosh, J.B. Leverenz, and E. Peskind et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders J Alzheimer Dis 9 2006 293 348
33. K.A. Jellinger, and J. Attems Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 112 2006 253 260
34. Y. Compta, M.J. Martí, N. Ibarretxe-Bilbao, C. Junqué, F. Valldeoriola, and E. Muñoz et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease Mov Disord 24 2009 2203 2210
35. M. Andersson, H. Zetterberg, L. Minthon, K. Blennow, and E. Londos The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia Int J Geriatr Psychiatry 26 2011 100 105
36. F. Bosttröm, O. Hansson, K. Blennow, L. Gerhardsson, T. Lundh, and L. Minthon et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies Dement Geriatr Cogn Disord 28 2009 314 319
37. C. Ballard, C. Ballard, I. Ziabreva, R. Perry, J.P. Larsen, and J. O'Brien et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum Neurology 67 2006 1931 1934
38. S. Baig, L.E. Palmer, M.J. Owen, J. Williams, P.G. Kehoe, and S. Love Clusterin mRNA and protein in Alzheimer's disease J Alzheimers Dis 28 2012 337 344
39. H. Gu, X. Wei, S. Chen, A. Kurz, U. Müller, and T. Gasser et al. Association of clusterin gene polymorphisms with late-onset Alzheimer's disease Dement Geriatr Cogn Disord 32 2011 198 201
40. Z.C. Wu, J.T. Yu, Y. Li, and L. Tan Clusterin in Alzheimer's disease Adv Clin Chem 56 2012 155 173
41. J.T. Yu, and L. Tan The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy Mol Neurobiol 45 2012 314 326
42. B. Schürmann, B. Wiese, H. Bickel, S. Weyerer, S.G. Riedel-Heller, and M. Pentzek et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration J Alzheimers Dis 25 2011 421 424
43. Y.Y. Xing, J.T. Yu, W.Z. Cui, X.L. Zhong, Z.C. Wu, and Q. Zhang et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease J Alzheimers Dis 29 2012 515 519
44. C. Sihlbom, P. Davidsson, M. Sjögren, L.O. Wahlund, and C.L. Nilsson Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals Neurochem Res 33 2008 1332 1340
45. E. Silajdžić, L. Minthon, M. Björkqvist, and O. Hansson No diagnostic value of plasma clusterin in Alzheimer's disease PLoS One 7 11 2012
46. K.D. van Dijk, W. Jongbloed, J.A. Heijst, C.E. Teunissen, H.J. Groenewegen, and H.W. Berendse et al. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease Parkinsonism Relat Disord 19 2013 1079 1083
47. J. Horvath, P.R. Burkhard, C. Bouras, and E. Kövari Etiologies of Parkinsonism in a century-long autopsy based cohort Brain Pathol 23 2013 28 33